News

Expanding on the efficacy shown in numerous single-group studies, a phase II study published in The Lancet Oncology showed lenalidomide significantly increased progression free survivalin patients with relapsed or refractory mantle cell lymphoma.

A combined homologous recombination deficiency score consisting of 3 markers significantly boosted outcome prediction of platinum-based treatment of ovarian cancer compared with the individual markers.

In an interview with Targeted Oncology, Stacy Loeb, MD discusses how these PSA tests work, what their benefits are, and what urological specialists need to know in order to best utilize them.

Patients with advanced ovarian cancer harboring mutations in homologous recombination (HR) genes, including BRCA1/2, had improved survival versus patients without HR mutations, according to a mutational analysis of the phase III GOG 218 study.

Investigators hope a duo of just-opened phase III studies will support expanding the FDA approval of olaparib (Lynparza) in ovarian cancer, according to Ursula A. Matulonis, MD.

Researchers are now working on refining the use of PARP inhibitors in ovarian cancer by gaining a greater understanding of mechanisms of resistance and exploring combination and sequencing possibilities. For expert insight on these topics, Targeted Oncology sat down with Shannon Westin, MD.

Trabectedin (Yondelis) improved progression-free survival (PFS) when compared with dacarbazine in women with advanced uterine leiomyosarcoma, according to a subgroup analysis of the phase III SAR-3007 trial.

Ghassan Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the significance of a recent trial and how the findings can impact the treatment paradigm of HCC.

The amount of vitamin D in a man's blood could be an effective biomarker to identify an aggressive form of prostate cancer, doubly so for men who are considering active surveillance.

An abiraterone acetate (Zytiga) plus prednisone combination showcased an 11.8-month improvement in overall survival (OS) when compared with prednisone and placebo in less advanced, chemotherapy-naive metastatic castration-resistant prostate cancer.

Men whose prostate cancer is treated with radiotherapy had a higher risk of developing secondary malignancies in the bladder, colon, and rectum, as compared with men who were not exposed to radiotherapy.

A recent study has shown that extracting cell-free DNA from urine is a highly effective technique for analyzing the genetic profile of urothelial bladder cancers.

The combination of nab-paclitaxel (Abraxane) and gemcitabine is steadily gaining in popularity among oncologists in the treatment armamentarium for pancreatic adenocarcinoma, according to Fadi Braiteh, MD.

The protein NOD-like receptor X1 (NLRX1) could be a potential biomarker to predict response for treatments in patients with colorectal cancer (CRC), according to a study published in Cell Reports.

Captisol-enabled (CE) melphalan (Evomela) has been approved by the FDA as a high-dose conditioning treatment for patients with multiple myeloma prior to autologous stem cell transplantation (ASCT).

Frontline treatment with CPX-351 (Vyxeos) significantly boosted overall survival (OS) for older patients with high-risk, secondary acute myeloid leukemia (AML).

The PD-L1 inhibitor atezolizumab has gained priority review status from the FDA as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC).

Six ongoing clinical trials investigating several idelalisib (Zydelig) combinations have been halted due to reports of increased adverse events such as death for patients with hematologic malignancies, according to an alert issued by the FDA.

The FDA has recieved a supplemental new drug application for a combination of ofatumumab (Arzerra), fludarabine, and cyclophosphamide, for patients with relapsed chronic lymphocytic leukemia (CLL).

The addition of Yttrium-90 (Y-90) resin microspheres (SIR-Spheres) to standard frontline FOLFOX-based chemotherapy with or without bevacizumab significantly improved liver-specific progression-free survival (PFS) for patients with liver metastatic colorectal cancer (CRC), according to findings from the phase III SIRFLOX study published in the Journal of Clinical Oncology.

Crizotinib (Xalkori) has been approved by the FDA for patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC), based on substantial efficacy displayed in a phase I study.

A recent publication from The Cancer Genome Atlas (TCGA) has opened the door wide for a slew of new, non-BRAF targeted agents in melanoma, according to Jason J. Luke, MD, FACP.

With the proven efficacy of both BREF/MEK inhibitors and immunotherapies, Jeffrey S. Weber, MD, PhD, discusses which to use first in patients with melanoma.

With updated data further proving its efficacy, Jonathan R. Strosberg, MD, says Lu-Dotatate 177 could be an excellent addition to oncologists' armamentarium against midgut neuroendocrine tumors (NETs).

Advances in kidney cancer deal much more in surgery, rather than treatment options, according to Alexander Kutikov, MD, FACS.

The PD-L1 inhibitor atezolizumab (MPDL3280A) showed promising antitumor activity in patients with inoperable locally advanced or metastatic urothelial carcinoma whose disease had progressed after previous platinum-based chemotherapy.

Immune checkpoint inhibitors have shown promising findings for patients with advanced bladder cancer, with data from phase II studies submitted to the FDA for consideration. The next question facing oncologists is how to optimally utilize these agents, according to James L. Gulley, MD, PhD.

Vitamin D deficiency could lead to a quickly growing primary tumor and a hastened development of metastases for patients with breast cancer, according to researchers at Stanford University School of Medicine.

A supplemental new drug application for pembrolizumab for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression on ≥1% of tumors cells has been submitted to the FDA.

The combination of rindopepimut plus temozolomide did not improve overall survival (OS) when compared with temozolomide plus a control in patients with newly diagnosed EGFRvIII-positive glioblastoma multiforme (GBM).